Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) Stock

About Zhejiang Huahai Pharmaceutical Co., Ltd.

Zhejiang Huahai Pharmaceutical Co., Ltd. is a China-based pharmaceutical enterprise with a global presence. Its diverse portfolio encompasses treatments for central nervous system disorders, cardiovascular conditions, and viral infections, among other finished pharmaceutical products. Beyond finished drugs, the company also produces Active Pharmaceutical Ingredients (APIs) and crucial intermediates. Huahai Pharmaceutical further engages in the manufacturing of packaging components, notably high-density polyethylene (HDPE) bottles and polypropylene (PP) caps. Additionally, it offers contract manufacturing (CMO) and other specialized services, while also playing a role in import and export trade services. Established in 1989, the company maintains its headquarters in Linhai, China.

Zhejiang Huahai Pharmaceutical Co., Ltd. is led by CEO Bao Hua Chen, employs 8,797 people, headquartered in Linhai, CN, publicly traded since 2003.

over the past 52 weeks the stock has ranged between $13.73 and $19.66, and currently trades 18.0% below its 52-week high.

Official website: www.huahaipharm.com

Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) — frequently asked questions